Sign in
Taking people in ChinaNo phase

PET Scans That Target CLDN18.2 in Gastric, Pancreatic and Bile Duct Cancers

Tests a PET scan that shows CLDN18.2 in tumors of adults with cancer.

Key facts

Who runs it
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Where
Wuhan, ChinaSee the site
Trial code
Registry title
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
Status
Recruiting
People taking part
56 people, planned
Started
1 Sept 2025
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • Specific PET imaging agents targeting CLDN18.2
Record updated
24 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with gastric, pancreatic, bile duct or esophageal cancer (suspected or diagnosed), and also healthy volunteers. All will have a PET scan with a CLDN18.2-targeted imaging agent.

Age
18-70 years
Sex
Men and women
Disease stage
Suspected or diagnosed malignant tumor such as gastric cancer, pancreatic cancer, bile duct cancer or esophageal cancer, in good general condition

Main reasons for not taking part

  • Cannot complete a PET/MR or PET/CT scan (for example cannot lie flat, claustrophobia, fear of radiation)
  • Other comorbidities
  • Known allergy to the CLDN18.2 PET imaging agent or its excipients
  • Fasting blood glucose above 11.0 mmol/L (198 mg/dL) before 18F-FDG injection
  • Poor compliance judged by the researcher

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Each participant must meet all inclusion criteria to be eligible to participate in the study:; The participant or their legal representative is able to sign the informed consent form with signature and date; Commit to adhering to the research procedures and cooperating in the implementation of the entire research process; Adult patients or healthy volunteers (aged 18-70 years), male or female; Patients with malignant tumors such as gastric cancer, pancreatic cancer, bile duct cancer, esophageal cancer, etc., suspected or diagnosed clinically (supporting evidence includes serum tumor markers, ultrasound, CT, MRI, and other imaging data, as well as histopathological examination), and in good general condition; Meet specific laboratory test results; Women of childbearing age must use contraception for at least one month before screening and commit to using contraception throughout the study period and continuing it until the specified time after the study ends; Other set inclusion criteria

Who cannot take part

  • All subjects who meet any exclusion criteria baseline will be excluded from the study:; Those unable to complete PET/MR or PET/CT scans (including those unable to lie flat, claustrophobia, radiation phobia, etc.); Those with other comorbidities; Patients known to be allergic to the targeted CLDN18.2 PET imaging agent or synthetic excipients; fasting blood glucose level exceeding 11.0 mmol/L before injection of 18F-FDG; Those with a history of concomitant medication use; Patients considered to have poor compliance by the researcher

Where in China

  • Wuhan Union Hospital, ChinaWuhan, ChinaContact: Xiaoli Lan, PhDTaking people

About the trial

What the trial wants to find out

The project aims to perform integrated PET/MR or PET/CT imaging in patients with histologically confirmed or clinically suspected gastric cancer, pancreatic cancer, cholangiocarcinoma, or other malignant tumors with high Claudin18.2 (CLDN18.2) expression, as well as healthy volunteers. This study utilizes a CLDN18.2-specific PET imaging probe (e.g., [\^68Ga]Ga-labeled humanized antibody fragment) to evaluate the feasibility, accuracy, and clinical value of non-invasive, in vivo CLDN18.2 visualization.

Read full original descriptionShow less

For patients with malignant tumors, the study will assess the diagnostic performance of CLDN18.2-targeted PET in identifying tumor lesions, compare the imaging results with gold-standard histopathology, determine the location, extent, and metabolic features of CLDN18.2-positive lesions, and evaluate tumor burden and treatment stratification value compared with [\^18F]FDG PET imaging. These results may assist in patient selection for CLDN18.2-targeted therapies (e.g., Zolbetuximab), guide clinical decision-making, and provide early prediction of therapeutic response.

For healthy volunteers, pharmacokinetic profiling will be conducted to investigate the biodistribution, clearance, and safety of the radiotracer in vivo.

Treatments tested

  • Specific PET imaging agents targeting CLDN18.2

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
Plain-language title
PET Scans That Target CLDN18.2 in Gastric, Pancreatic and Bile Duct CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
24 December 2025